5300438
Last Update Posted: 2024-06-25
Recruiting has ended
All Genders accepted | 18 Years + |
74 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.
Eligibility
Relevant conditions:
Cancer (With or Without Metastasis)
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Cindy Li
li_jing_cindy@tyligand.com
+86-021-50720081
Data sourced from ClinicalTrials.gov